RVXCF (Resverlogix) Purchase Of Business : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Purchase Of Business?

Resverlogix's purchase of business for the three months ended in Dec. 2024 was $0.00 Mil. It means Resverlogix spent $0.00 Mil on purchasing business. Resverlogix's purchase of business for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2024 ), Resverlogix spent the same money on purchasing business in Dec. 2024 ($0.00 Mil).

Resverlogix Purchase Of Business Historical Data

The historical data trend for Resverlogix's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Purchase Of Business Chart

Resverlogix Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Purchase Of Business

Get a 7-Day Free Trial

Resverlogix Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Purchase Of Business	Get a 7-Day Free Trial															-	-	-	-	-

Resverlogix Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Resverlogix Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Resverlogix's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Purchase Of Business

Comparable Companies

Traded in Other Exchanges

RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.